Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE 7: Darolutamide and Stereotactic Dose Escalated Radiotherapy in Localized Prostate Cancer
NCT06625970Phase 3Recruiting
- Sponsor
- Unicancer
- Start
- Apr 2025
- Primary completion
- Oct 2033
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of darolutamide in prostate cancer (PCa), sponsored by Unicancer. Started Apr 2025; status: recruiting.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06625970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625970.